Coston McIsaac & Partners’s Bristol-Myers Squibb BMY Stock Holding History

Coston McIsaac & Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115K	Hold	2,010	–	–	0.02%	220
2026 Q1	$121K	Hold	2,010	–	–	0.03%	208
2025 Q4	$108K	Buy	2,010 +78	+4%	+$3.75K	0.03%	212
2025 Q3	$87K	Buy	1,932 +6	+0.3%	+$280	0.02%	239
2025 Q2	$89K	Buy	1,926 +10	+0.5%	+$491	0.02%	228
2025 Q1	$116K	Sell	1,916 -158	-8%	-$9.21K	0.03%	173
2024 Q4	$117K	Buy	2,074 +233	+13%	+$13K	0.03%	174
2024 Q3	$95K	Hold	1,841	–	–	0.03%	191
2024 Q2	$76K	Hold	1,841	–	–	0.02%	209
2024 Q1	$99K	Hold	1,841	–	–	0.03%	179
2023 Q4	$94K	Buy	1,841 +22	+1%	+$1.16K	0.03%	179
2023 Q3	$105K	Sell	1,819 -24	-1%	-$1.47K	0.04%	159
2023 Q2	$117K	Hold	1,843	–	–	0.04%	158
2023 Q1	$127K	Hold	1,843	–	–	0.05%	151
2022 Q4	$132K	Hold	1,843	–	–	0.05%	145
2022 Q3	$131K	Sell	1,843 -1	-0.1%	-$73	0.06%	128
2022 Q2	$142K	Buy	+1,844	New	+$140K	0.09%	83

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Coston McIsaac & Partners's BMY Position: Q2 2026 in Review

Coston McIsaac & Partners held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 2,010 shares worth $115K. The position accounts for 0.02% of the portfolio, ranked #220.

Coston McIsaac & Partners first reported a position in BMY in Q2 2022 and has held it in 17 quarters since. The position peaked at $142K in Q2 2022. 2,524 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Coston McIsaac & Partners held 2,010 shares of Bristol-Myers Squibb worth $115K as of Q2 2026.
Coston McIsaac & Partners left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.02% of Coston McIsaac & Partners's portfolio in Q2 2026, its #220 holding.
Coston McIsaac & Partners first reported a position in Bristol-Myers Squibb in Q2 2022 and has held it in 17 quarters since.
Coston McIsaac & Partners's Bristol-Myers Squibb position peaked at $142K in Q2 2022.
2,524 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.